Our Research
Our research group performs a variety of studies in the general areas of inorganic, bioinorganic, medicinal, materials, and supramolecular chemistry. Some of our current focus areas are summarized below
Our research group performs a variety of studies in the general areas of inorganic, bioinorganic, medicinal, materials, and supramolecular chemistry. Some of our current focus areas are summarized below
For more than 15 years our group has explored the chemistry of the microporous solids known as metal-organic frameworks (MOFs). Our studies have spanned a wide range of topics with MOFs, largely focusing on synthetic methods, including postsynthetic modification (PSM). Many of our more recent studies have been focused on MOF-polymer composite materials and low-valent MOFs.
For more than 20 years our group has developed approaches to apply fragment-based drug discovery (FBDD) to the development of metalloenzyme inhibitors. Our studies have targeted metalloenzymes implicated in a wide range of illness, from cancer to infectious disease. Many of our more recent studies have been focused the development of metal-binding isosteres (MBIs) and targeted protein degradation (TPD) of metalloenzymes.
Within the last 4 years our group has explored the use of 'metallofragments' for fragment-based drug discovery (FBDD). Metallofragments seek to exploit the inherent 3-dimensionality and reactivity of metal complexes for discovering new bioactive molecules. Our studies have examined a variety of disease-relevant targets, including the main protease of SARS-CoV-2 (e.g., COVID-19).
Over the course of our investigations, our group has explored a variety of topics in bioinorganic, medicinal, inorganic, materials, and supramolecular chemistry. Some of these led to larger projects, while others consisted of just short-term or one-off studies..
Website Building Software